Hangzhou Tigermed Consulting CoFRA:5HZ1 +5.41%86 EBITDA Margin % is 11.09% as of Mar. 2026, which is 68% below its 10-year median of 34.59. GuruFocus rates FRA:5HZ1 with a GF Score™ of 86/100 and a GF Value™ of €5.04 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Hangzhou Tigermed Consulting Co ranks better than 65.02% on this metric.
Hangzhou Tigermed Consulting Co (FRA:5HZ1) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Hangzhou Tigermed Consulting Co EBITDA Margin % Related Terms
Hangzhou Tigermed Consulting Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Tigermed Consulting Co EBITDA Margin % Chart
FRA:5HZ1 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Hangzhou Tigermed Consulting Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hangzhou Tigermed Consulting Co EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Hangzhou Tigermed Consulting Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Hangzhou Tigermed Consulting Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hangzhou Tigermed Consulting Co (FRA:5HZ1) has a EBITDA Margin % of 11.09% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hangzhou Tigermed Consulting Co and its competitors. This is 68% below median its historical median of 34.59. Over the past decade, Hangzhou Tigermed Consulting Co's EBITDA Margin % has ranged from 15.65 to 75.63. According to the industry distribution chart, Hangzhou Tigermed Consulting Co ranks #71 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 35%.
Is Hangzhou Tigermed Consulting Co's EBITDA Margin % too high?
Hangzhou Tigermed Consulting Co's current EBITDA Margin % of 11.09% is 68% below median its 10-year median of 34.59. Over the past 10 years, this metric has ranged from a low of 15.65 to a high of 75.63. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.00. Hangzhou Tigermed Consulting Co's value of 11.09% is 121.8% above this industry median. Based on the distribution chart, Hangzhou Tigermed Consulting Co ranks #71 out of 203 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Hangzhou Tigermed Consulting Co has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hangzhou Tigermed Consulting Co's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Hangzhou Tigermed Consulting Co ranks #71 out of 203 companies for EBITDA Margin %. This puts Hangzhou Tigermed Consulting Co in the upper half of its industry. The industry median EBITDA Margin % is 5.00. Hangzhou Tigermed Consulting Co's value of 11.09% is 121.8% above this benchmark. Historically, Hangzhou Tigermed Consulting Co's own EBITDA Margin % has ranged from 15.65 to 75.63 over the past decade. While the company's 10-year median is 34.59 vs. the industry median of 5.00, Hangzhou Tigermed Consulting Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.00, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hangzhou Tigermed Consulting Co's current EBITDA Margin % of 11.09% is 121.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Hangzhou Tigermed Consulting Co and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hangzhou Tigermed Consulting Co's current EBITDA Margin % is 11.09%, which is 68% below median its own 10-year median of 34.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hangzhou Tigermed Consulting Co stock overvalued right now?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co (FRA:5HZ1) is currently considered Modestly Undervalued. The stock's GF Value™ is €5.04, compared to a current price of €3.90 — trading 22.6% below its estimated fair value. The current EBITDA Margin % is 11.09%, which is 68% below median its 10-year median of 34.59 and 121.8% above the Medical Diagnostics & Research industry median of 5.00. Hangzhou Tigermed Consulting Co's overall GF Score™ is 86/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Hangzhou Tigermed Consulting Co (FRA:5HZ1), the current EBITDA Margin % is 11.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hangzhou Tigermed Consulting Co (FRA:5HZ1) Overvalued in 2026?
Based on GuruFocus' analysis, Hangzhou Tigermed Consulting Co stock appears to be undervalued.
The current stock price of €3.90 is trading 22.6% below its estimated GF Value™ of €5.04.
GuruFocus considers Hangzhou Tigermed Consulting Co to be Modestly Undervalued.
Key valuation signals for FRA:5HZ1:
EBITDA Margin %: 11.09% (68% below median its 10-year median of 34.59)
GF Value™: €5.04 vs. price of €3.90 (22.6% below fair value)
Industry Position: 121.8% above the Medical Diagnostics & Research median (#71 of 203)
No single metric tells the full story. See the FRA:5HZ1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hangzhou Tigermed Consulting Co Business Description
Hangzhou Tigermed Consulting Co Ltd is a China-based provider of comprehensive biopharmaceutical R&D services, with an expanding world-wide presence. The Group is principally engaged in CRO services.
86GF Score
Get the complete analysis for FRA:5HZ1
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5HZ1 has been successfully added to your 
